Advertisement
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor

Daniela S. Bundschuh, Manfrid Eltze, Johannes Barsig, Lutz Wollin, Armin Hatzelmann and Rolf Beume
Journal of Pharmacology and Experimental Therapeutics April 2001, 297 (1) 280-290;
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor

Daniela S. Bundschuh, Manfrid Eltze, Johannes Barsig, Lutz Wollin, Armin Hatzelmann and Rolf Beume
Journal of Pharmacology and Experimental Therapeutics April 1, 2001, 297 (1) 280-290;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement